Eric Devroe - 01 Mar 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Operating Officer
Issuer ticker: ACRV
Reported as of: 01 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:16:29 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 03 Mar 2026.

Key facts

This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:16.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001950573 Primary reporting owner

Devroe Eric

Relationship: Chief Operating Officer
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 03 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +186,728
Change %
Price: $0.000000
Shares after: 186,728
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 186,728
Exercise price: $1.51
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.